Paclitaxel plus Cirmtuzumab Achieves Greater Clearance of Patient-derived Xenografts By Targeting ROR1+ Breast Cancer Stem Cells. Paclitaxel plus Cirmtuzumab Achieves Greater Clearance of Patient-derived Xenografts By Targeting ROR1+ Breast Cancer Stem Cells
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA427913
下载链接
链接失效反馈官方服务：
资源简介：
We applied high-throughput sequence to identify signaling pathways, stem cell gene signature or target genes of BMI1 that were affected by our newly development humainzed anti-ROR1 antibody (cirmtuzumab) in breast cancer patient-derived xenograft (PDX) mice model Overall design: Examination of 8 PDX samples isolated from control-treated mice (N=4) versus cirmtuzumab-treated mice (N=4)
创建时间：
2017-12-29
